Back

Acoramidis improves health-related quality of life in wild-type and variant transthyretin amyloid cardiomyopathy: An EQ-5D-5L subgroup analysis from ATTRibute-CM

30 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: New insights into cardiac amyloidosis Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Emer Joyce

Mater Misericordiae University Hospital, Dublin (Ireland)

7 More presentations in this session

Presentation thumbnail
Decoding peripartum cardiomyopathy through multi-omics: circulating and cellular signatures from the Italian multicenter registry
Doctor M. Carotenuto (Naples, IT)
Abstract
Presentation thumbnail
Premature hypertensive heart disease in working-age adults: global burden, inequalities and missed prevention opportunities (GBD 2021)
Doctor X. Dong (Beijing, CN)
Abstract
Presentation thumbnail
Vascular dysfunction is associated with symptom severity and quality of life in wild-type transthyretin amyloid cardiomyopathy
Mr N. Ogasawara (Akita, JP)
Abstract
Presentation thumbnail
Diagnostic utility of three clinical scoring systems for transthyretin amyloid cardiomyopathy in elderly Asian patients with heart failure with preserved ejection fraction
Doctor M. Chen (Taipei, TW)
Abstract
Presentation thumbnail
Improvement of health status with acoramidis in patients with wild-type and variant transthyretin amyloid cardiomyopathy: KCCQ domains analysis from the ATTRibute-CM study
Doctor N. Sarswat (Chicago, US)
Abstract

Access the full session

Session thumbnail
New insights into cardiac amyloidosis

The Event

Event poster

ESC Congress 2026

30 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension
30 August 2024
thumbnail
Congress Presentation
Effect of telemedicine on health-related quality of life in patients with heart failure: insights from the iCOR randomised controlled trial
21 May 2023
thumbnail
Congress Presentation
Health-related quality of life in patients with symptomatic transthyretin amyloid cardiomyopathy treated with acoramidis: an EQ-5D analysis from the ATTRibute-CM study
13 May 2024
thumbnail
Congress Presentation
Patient-reported outcome measures in wild-type and variant cardiac transthyretin amyloidosis: the ITALY (impact of transthyretin amyloidosis on life quality) study
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources